COSMETIC TREATMENT PROCEDURE BY COMBINED ILLUMINATION AND APPLICATION OF A COMPOSITION WITH AN EPILOBIUM EXTRACT AND ASSOCIATED DEVICE

Description

TECHNICAL FIELD

[0001] The invention relates to the field of non-therapeutic cosmetic treatments using skin illumination. The invention also relates to the field of cosmetic treatments involving the application of a composition comprising at least one active ingredient.

[0002] The invention relates more particularly to a non-therapeutic treatment intended to limit skin disorders related to so-called oily skin.

[0003] The invention further relates to a device for implementing such a process. EARLIER ART

[0004] Oily or oily-prone skin is characterized by a significant secretion of sebum. Sebum is primarily composed of lipids, mainly triglycerides, waxes (fatty acid esters), and alcohols. Sebum is secreted by sebaceous glands located beneath the skin's surface and most often connected to a hair follicle. At the periphery of the sebaceous glands, differentiated cells called sebocytes synthesize various fatty substances, including sebum, and release their contents into the sebaceous gland.

[0005] Excessive sebum production gives the skin a shiny appearance. Often, the skin also exhibits dilated follicular openings. Inflammatory complications can also be observed in oily skin, caused by various factors, including bacterial overgrowth.

[0006] There are treatments designed to reduce the unsightly and inflammatory effects of oily skin. However, these treatments are often either ineffective or based on synthetic products that can cause other undesirable effects on the skin, such as increased dryness.

[0007] US2016 / 089310 A1 discloses an active composition comprising an extract of Epilobium fleischeri as an active ingredient to control sebum.

[0008] The invention aims to provide an effective treatment against such skin disorders, in particular to reduce sebum production and mattify the skin.

[0009] The invention also aims to provide a treatment which also corrects imperfections and tightens pores.

[0010] The invention ultimately aims to provide a treatment that is both effective against skin disorders associated with oily skin, and that also contributes to the general improvement of the skin's condition.

[0011] To this end, the invention relates to a non-therapeutic cosmetic treatment process comprising at least the following steps: application to the skin of a subject of an active composition comprising at least one extract of 'Epilobium fleischeri, and illumination of the skin by at least one light source emitting at a wavelength between 490 and 550 nanometers, preferably 520 nanometers, the illumination being carried out before, simultaneously or after the application of the composition.

[0012] The method of the invention may also include the following optional features considered individually or in all possible technical combinations: The active composition further includes salicylic acid. The active composition further includes artichoke extract. The active composition further includes niacinamide, and skin illumination is further achieved by a light source emitting at a wavelength between 620 and 690 nanometers, preferably 660 nanometers. Skin illumination is further achieved by a light source emitting at a wavelength between 410 and 470 nanometers, preferably between 440 and 450 nanometers. The mass percentage of extract of Epilobium the percentage in the composition is between 0.1 and 10%.

[0013] The invention further relates to a non-therapeutic cosmetic treatment device comprising at least means for applying to the skin of a subject an active composition comprising at least one extract of Epilobium fleischeri,which active composition is contained in the application means, and means for illuminating the skin by at least one light source emitting at a wavelength between 490 and 550 nanometers, preferably 520 nanometers, the means for illuminating and applying the active composition being configured so that illumination can be carried out before, simultaneously or after the application of the composition.

[0014] Advantageously, the active composition further includes niacinamide, and the means of skin illumination further include a light source emitting at a wavelength between 620 and 690 nanometers, preferably 660 nanometers.

[0015] Even more advantageously, the active composition further includes salicylic acid and artichoke extract, and the means of skin illumination further include a light source emitting at a wavelength between 410 and 470 nanometers, preferably between 440 and 450 nanometers.

[0016] Other features and advantages of the invention will become clear from the description given below, which is by way of example and not limitation, with reference to the attached figures: [ Fig 1 ] There figure 1 is a histogram illustrating lipid production in sebocytes through the fluorescence signal intensity of a marker, the sebocytes having been exposed to UVB and treated by the application of a composition including an extract of Epilobium fleischeri and various illuminations, including one emitting at a wavelength of 520 nanometers; [ Fig 2 ] There figure 2 is a histogram illustrating lipid production in sebocytes exposed to UVB, through the ratio between the Nile Red signal and the Hoechst signal, treated by illumination alone emitting at different wavelengths including a wavelength of 520 nanometers, treated by the application alone of a composition including an extract of Epilobium fleischeri, and treated by combining illumination emitting at different wavelengths, including a wavelength of 520 nanometers, and a composition including, in particular, an extract of Epilobium fleischeri ; Fig 3 ] There figure 3 is a histogram illustrating the amount of interleukin 6 present in sebocytes that have been exposed to UVB, treated by illumination alone emitting at different wavelengths including a wavelength of 520 nanometers, treated by the application alone of a composition including an extract of Epilobium fleischeriand treated by combining illumination emitting at different wavelengths, including a wavelength of 520 nanometers, and a composition including, in particular, an extract of Epilobium fleischeri ; Fig 4 ] There figure 4 is a histogram illustrating the percentage of stimulation of procollagen-1 production in cells previously exposed to a combination of UVA and UVB and treated by illumination alone at a wavelength of 660 nanometers, by the application of niacinamide alone, and by a treatment process with a composition containing niacinamide and discontinuous illumination at a wavelength of 660 nanometers, and by illumination alone at a wavelength of 660 nanometers. Fig 5 ] There figure 5is a histogram illustrating the distribution of lipid droplet volume in sebaceous glands exposed to UVB, treated with illumination alone emitting at different wavelengths including a wavelength of 520 nanometers, treated with a composition alone including an extract of Epilobium fleischeri and treated by combining illumination emitting at different wavelengths, including a wavelength of 520 nanometers, and a composition comprising an extract of Epilobium fleischeri ; Fig 6 ] There figure 6 is a graph illustrating the evolution of facial skin hydration in a woman (clinical evaluation) who underwent the cosmetic treatment process of the invention on the first day of treatment, the 14th day of treatment, and the 28th day of treatment; Fig 7 ] There figure 7is a graph illustrating the evolution of the number of imperfections on the facial skin of a woman (clinical evaluation) who underwent the cosmetic treatment process of the invention on the first day of treatment, the 14th day of treatment and the 28th day of treatment; Fig 8 ] There figure 8 is a graph illustrating the evolution of the radiance of a woman's facial skin (clinical evaluation) who underwent the cosmetic treatment process of the invention on the first day of treatment, the 14th day of treatment, and the 28th day of treatment; Fig 9 ] There figure 9 is a graph illustrating the evolution of the smoothness of the facial skin of a woman (clinical evaluation) who underwent the cosmetic treatment process of the invention on the first day of treatment, on the 14th day of treatment and on the 28th day of treatment; Fig 10 ] There Figure 10is a graph illustrating the evolution of the amount of sebum on the forehead of a woman's face (quantitative measurements) who has undergone the cosmetic treatment process of the invention on the first day of treatment, the 14th day of treatment, and the 28th day of treatment; Fig 11 ] There figure 11 is a graph illustrating the evolution of the average pore size of a woman's facial skin (quantitative measurements) who has undergone the cosmetic treatment process of the invention on the first day of treatment, the 14th day of treatment, and the 28th day of treatment; Fig 12 ] There figure 12 is a schematic cross-sectional representation of the device of the invention without its composition application capsule, [ Fig 13 ] There figure 13 is a schematic cross-sectional representation of the device of the invention illustrated with the composition application capsule, and [ Fig 14 ] There figure 14is a schematic front view representation of an example embodiment of the electroluminescent device of the device of the invention of Figures 12 And 13 . [ Fig 15 ] There figure 15 is a histogram illustrating the percentage of lipids relative to the number of cells (nuclei) for sebocytes respectively untreated, supplemented with LDS (Liquid Droplet Stimulator), supplemented with LDS, exposed to UVB, and treated with an extract of 'Epilobium fleischeri, and supplemented with LDS, exposed to UVB and treated with an extract of 'Epilobium fleischeri and an illumination emitting at 520 nanometers. DETAILED DESCRIPTION OF THE INVENTION

[0017] The cosmetic treatment method of the invention is a non-therapeutic method that applies exclusively to skin free of open wounds and any other pathology. The cosmetic treatment method of the invention is applicable to skin described as "oily," that is to say, skin primarily subject to excessive sebum production.

[0018] The cosmetic treatment process of the invention essentially comprises a step of applying to the skin of a subject a composition comprising at least one extract of 'Epilobium fleischerias the active agent, and illumination, preferably simultaneously, of the same area of ​​skin by a light source emitting in the green spectrum at a wavelength of approximately 520 nm, considering a half-bandwidth of 30 nm. When illumination is performed before or after application of the composition, a maximum time between illumination and application of niacinamide of 30 minutes, preferably 15 minutes, is considered.

[0019] The cosmetic treatment method of the invention may advantageously include the simultaneous application of niacinamide to the subject's skin coupled with illumination by a light source emitting in the red spectrum at a wavelength of approximately 660 nm, considering a half-bandwidth of 30 nm. The additional application of niacinamide and illumination with red light provides skincare benefits in addition to reducing the undesirable effects of oily skin, as will be detailed later.

[0020] The process of the invention significantly reduces lipid production by sebocytes, as well as their inflammatory nature. The process of the invention also significantly reduces, ex vivo, the volume of lipids produced by the sebaceous glands. Finally, the clinical tests, which will be detailed later, demonstrate, in addition to the reduction in the amount of sebum on the skin and the associated shine, improved skin hydration, a reduction in blemishes, and an overall improvement in skin quality.

[0021] In vitro assays of lipid production in a sebocyte culture subjected to different treatments were conducted. Three days after inoculation, the sebocytes were irradiated with UVB and then subjected to the treatment. The treatment was repeated on the fourth day. Five days after inoculation, the sebocytes were again irradiated with UVB and then subjected to the treatment. The treatment was repeated on the sixth day. The cultures were harvested for analysis on the seventh day.

[0022] The treatment consists of the application of an aqueous serum whose composition is given in Table 1 below. [Table 1]: Serum composition Alpaflor (Epilobium Fleischeri extract) 1.0% by weight Niacinamide 3.0% by weight Artichoke extract 1.0% by weight Salicylic acid 0.5% by weight Vitamin C 0.2% by weight

[0023] The treatment also consists of concomitant illumination with the application of the composition according to the four illumination programs defined in Table 2 below. [Tables 2]: Parameters associated with each tested lighting program Program 1 2 Wavelength (nm) Intensity (mA) Irradiance (mW / cm2) Intensity (mA) Irradiance (mW / cm2) 440 214 7,4 244 8,5 520 - - 244 8,2 660 244 11 244 10,6 940 220 3,7 - - Program 3 4 Wavelength (nm) Intensity (mA) Irradiance (mW / cm2) Intensity (mA) Irradiance (mW / cm2) 440 117 4,1 489 16,9 520 - - - - 660 98 4,2 489 21,2 940 64 1,1 489 8,2

[0024] We refer to the figure 1 illustrating, in histogram form, lipid production in sebocytes through the intensity of the fluorescence signal of a marker. On this figure 1Reference 1 corresponds to sebocytes that have not undergone irradiation or treatment, reference 2 corresponds to UVB irradiation not followed by treatment, reference 3 corresponds to treatment by application of the serum and illumination according to illumination program 1 after UVB irradiation, reference 4 corresponds to treatment by application of the serum and illumination according to illumination program 2 after UVB irradiation, reference 5 corresponds to treatment by application of the serum and illumination according to illumination program 3 after UVB irradiation, and reference 6 corresponds to treatment by application of the serum and illumination according to illumination program 4 after UVB irradiation.

[0025] The results presented on the figure 1Sebocyte cultures are obtained by sampling sebocytes on the seventh day after inoculation and labeling the cells with Nile Red. This marker is known in the study of lipid structures for its fluorescence properties in hydrophobic media. It forms a hydrophobic probe that integrates into lipid structures. By integrating the fluorescence signal obtained with Nile Red, an estimate of the amount of lipids (sebum) in the sebocytes is obtained.

[0026] It was observed that while all four illumination programs (Table 2) combined with serum application (Table 1) reduced the amount of sebum secreted by sebocytes, illumination program 2, the only one to include green light illumination at a wavelength of 520 nm, resulted in the greatest reduction in sebum secretion. This illumination program 2 was used in the subsequent tests.

[0027] With reference to figures 2 And 3 , further tests were conducted on sebocyte cultures according to the same protocol as previously indicated (inoculation, UVB irradiation on days three and five, application of daily treatment from day three to day six, and culture recovery on day seven) to demonstrate the synergy between the serum containing the extract of 'Epilobium Fleischeri and illumination program 2 including illumination at a wavelength of 520nm.

[0028] In these figures, reference 7 corresponds to reference sebocyte cultures that have not undergone UVB irradiation or subsequent treatment. Reference 8 corresponds to sebocyte cultures that have been irradiated only with UVB. Reference 9 corresponds to sebocyte cultures that have been irradiated with UVB and treated only by serum application. Reference 10 corresponds to sebocyte cultures that have been irradiated with UVB and treated only by illumination according to program 2. And reference 11 corresponds to sebocyte cultures that have been irradiated with UVB and treated by serum application and combined illumination according to program 2.

[0029] The results presented on the figure 2 confirm the results presented on the figure 1 in that the combined application of serum comprising the extract d'Epilobium FleischeriIllumination according to illumination program 2, which includes illumination at a wavelength of 520 nm, substantially reduces sebum secretion by sebocytes. This assessment is performed by calculating the ratio between the Nile Red signal, which reflects the lipid content in sebocytes, and the Hoechst signal, which reflects the number of cells.

[0030] It is also observed that this joint application of serum and illumination results in a better reduction of sebum secretion than the application of serum alone or illumination alone, thus highlighting the synergy between serum and illumination according to illumination program 2.

[0031] The results presented on the figure 3They also allow us to highlight the synergy between the serum and illumination according to illumination program 2 with regard to reducing inflammation. Indeed, the figure 3 demonstrates a significant reduction in the concentration of interleukin-6 released by sebocytes for the treatment of the invention's process. This synergy is all the more striking given that the sole application of the serum (reference 9) and the sole illumination by the illumination program 2 (reference 10) lead to a slight reduction in the concentration of interleukin-6.

[0032] The results presented on the figures 2 And 3These results demonstrate, respectively, a reduction in lipid production by sebocytes and a reduction in the release of interleukin-6 in cultures subjected to the treatment process of the invention. These two parameters must be considered together, since in the case of a complete tissue, it is known that inflammation amplifies sebum production. Thus, the treatment process of the invention, acting not only on sebum production but also on inflammation, is substantially effective for treating oily skin.

[0033] Ex vivo studies on lipid production in sebaceous glands subjected to different treatments were conducted. One day after inoculation, the sebaceous glands were irradiated with UVB and then subjected to the treatment. The treatment was applied daily until the fourth day. On the third day, the sebaceous glands were again irradiated with UVB before the daily treatment was applied. The cultures were collected for analysis on the fifth day. The collected cultures underwent color labeling of the lipid droplets. Confocal imaging was used to reconstruct the sebaceous glands in three dimensions and to measure the quantity and size of the lipid droplets.

[0034] There figure 5This illustrates the results obtained in terms of the distribution of the volume of lipid droplets contained in sebaceous glands from cultures. Reference 12 corresponds to an untreated sebaceous gland. Reference 13 also corresponds to an untreated sebaceous gland. Reference 14 corresponds to a sebaceous gland that was treated only by the application of serum (Table 1). Reference 15 corresponds to a sebaceous gland treated only by illumination according to illumination program 2 (Table 2). And reference 16 corresponds to sebaceous glands treated by the process of the invention, namely a combination of serum application and illumination according to illumination program 2.

[0035] It is observed that the greatest reduction in the distribution of lipid droplet volume in the sebaceous glands is obtained with a treatment according to the invention combining serum application and illumination with green light (reference 16). These results further confirm the synergistic effect between serum application and illumination at a wavelength of 520 nm.

[0036] These results are further corroborated by the figure 15 which illustrates the results obtained in terms of lipid percentages relative to the number of cells for sebocytes that were respectively untreated (reference 50), supplemented with LDS (Lipid Droplet Stimulator) (reference 51), exposed to UVB, and treated by the application of an extract of Epilobium fleischeri (reference 52), and exposed to UVB and treated by the combined application of an extract of Epilobium fleischeriand illumination by green light alone at a wavelength of 520 nm (reference 53). For these last two treatments, the sebocytes are also supplemented with LDS.

[0037] The sebocytes used in these results are cultured for 9 days, and the culture medium is changed daily starting on day 5. It is also on day 5 that the sebocytes are first exposed to UVB and treated by applying the extract of Epilobium fleischeri and, if necessary, illumination with green light. A second UVB exposure is carried out on day 7, while the treatment involves applying the extract of Epilobium fleischeri and where appropriate, green light illumination is applied on days 6, 7 and 8. Day 9 marks the end of treatment and the beginning of analyses.

[0038] Compared to untreated sebocytes (reference 50) and untreated sebocytes supplemented with LDS (reference 51), it is observed that if the extract of 'Epilobium fleischeri alone (reference 52) induces a significant effect on lipid production by sebocytes; it is indeed the combined application of the extract of Epilobium fleischeri and green light (reference 53) which allows us to find a percentage of lipids produced by sebocytes close to that of untreated sebocytes.

[0039] Clinical trials were conducted on 32 women aged 20 to 40 with phototypes I to III. For 28 days, these women received the treatment according to the method of the invention 6 days out of 7. The illumination corresponds to program 2 shown in Table 2, and the composition is that indicated in Table 1. The treatment is performed by simultaneous application of the composition and the illumination according to program 2. The treatment according to the invention is carried out on 12 areas from the chin to the forehead (6 areas per half of the face). Each area is treated for 15 seconds according to program 2; the facial treatment is thus completed in 3 minutes.

[0040] A specialist clinically assesses the effects of the treatment after 14 days (reference 18 on the figures 6 to 9 ) and 28 days (reference 19 on the figures 6 to 9 ), compared to the first day of treatment (reference 17 on the figures 6 to 9), on skin hydration, radiance, the number of imperfections, and skin smoothness. For skin hydration, radiance, and smoothness, the results are from a clinical scoring assessment performed by a specialist. In reference to the figure 10 The amount of sebum on the skin is measured using a sebumeter after 14 days (reference 18) and 28 days (reference 19), compared to the first day of treatment (reference 17). Finally, with reference to the figure 11 The average pore size is evaluated by high-definition image analysis according to the same protocol.

[0041] It is observed that for all parameters tested, whether clinically evaluated or measured, the process of the invention improves the quality of the skin in terms of its hydration, the reduction of its imperfections, the reduction of shine, and also its softness.

[0042] The process of the invention involves several active agent / wavelength pairs. In addition to the combination of the extract of Epilobium fleischeri and green light illumination, the treatment also includes a combination of niacinamide and red light. With reference to the figure 4The percentage increase in procollagen-1 production was measured in cells previously exposed to a combination of UVA and UVB light and treated with illumination alone at a wavelength of 660 nanometers, with niacinamide alone, and with a treatment combining a composition containing niacinamide and intermittent illumination at a wavelength of 660 nanometers. Reference 20 corresponds to treatment with niacinamide alone, reference 21 to treatment with 660 nm illumination alone, and reference 22 to treatment combining the effects of niacinamide and 660 nm illumination. Increased procollagen-1 production was observed following treatment combining niacinamide and red light illumination.This niacinamide / red light combination, which may be present in the treatment process of the invention, provides additional care for oily skin to improve the overall condition of the skin. This is also the case for the moisturizing effect (. figure 6 ) of the treatment process of the invention which is opposed to the majority of existing treatments for oily skin which, on the contrary, tend to dry out the skin.

[0043] Thus, the treatment process of the invention, in addition to significantly reducing sebum production and the inflammatory character also involved in sebum production, acts as a treatment by improving the general condition of the skin.

[0044] The treatment process of the invention finds application not only for the aesthetic treatment of oily skin, but for all types of seborrhea in general (seborrheic dermatitis for example).

[0045] The invention further relates to a device for implementing the method of the invention. The device of the invention is described with reference to the figures 12 And 13 .

[0046] The device 30 comprises a generally cylindrical housing 31 containing an electroluminescent device 32 and a removable capsule 33 for applying the composition to the skin. The walls of the device have an embossed section that is purely aesthetic. The electroluminescent device 32 mainly comprises a series of light-emitting diodes (LEDs) 29 distributed regularly and circumferentially around the main axis XX' on the side of a first end 30a of the device 30 and mounted on a dedicated electronic board 34. Each LED 29 is surmounted by a lens 35 forming a light guide and ensuring the focusing of the light emitted by the LEDs 29 in a controlled direction, as will be explained later. In a preferred embodiment, nine LEDs 29 are arranged circumferentially on the electronic board 34.The LEDs are electrically connected to a battery 36 located at the handle of the device 30 on the side of its opposite end 30b.

[0047] With reference to the figure 13 The device includes, upstream of the LEDs 29 on the side of its first end 30a, a housing 37 for receiving the removable capsule 33. This housing 37 has a general frustoconical shape but can have any suitable shape coinciding with the structure of the external wall of the capsule 33. Two diametrically opposed hooks 38 are provided near the opening 39 of the housing 37 to ensure the removable attachment of the capsule 33 inserted in the receiving housing 37 according to the arrow F.

[0048] With reference to the figure 13The capsule 33 mainly comprises a removable cap 40 relative to said capsule 33, a ball-shaped dispenser 41, a composition reservoir 43 connected to the dispenser 41 by at least one opening 42 ensuring the distribution of the composition onto the surface of the ball 41, and a bottom wall 44 that slides relative to the ball 41 between a position furthest from the ball 41 in which the composition remains in the reservoir 43, and a position closest to the ball 41 in which the composition, or a part of the composition, contained in the reservoir 43 is released onto the surface of the ball 41. The side walls 45 of the capsule 33 are translucent or transparent to ensure the diffusion of light onto the surface and in the intended direction.More specifically, the lenses 35 associated with the LEDs 29 are configured to distribute the emitted light within the walls 45 of the capsule, which are themselves configured to converge the light at the distribution sphere 41, thus illuminating the area of ​​skin to which the composition is simultaneously applied. Furthermore, the distribution sphere 41 is held in place by a collar 48, an extension of the capsule's lateral walls 45, which is also translucent or transparent. Therefore, during illumination, the light is distributed not only at the distribution sphere 41 as previously described, but also through the collar 48.

[0049] When the capsule 33 is inserted into the receiving compartment 37, the bottom wall 44 makes contact with a piston 46. The axial movement of the piston 46 towards the capsule 33 is driven by a motor 47 connected to the battery 36. This axial movement of the piston 46 (not shown) pushes the bottom wall 44 of the capsule 33 towards the dispensing ball 41 along a defined stroke corresponding to the distribution of a dose of the composition. This releases the composition contained in the reservoir 43 onto the surface of the dispensing ball 41, which is designed to roll over the surface of the skin to be treated, thus applying the composition. During the next use, the piston 46 again drives the bottom wall 44 axially towards the dispensing ball 41 along a new stroke to deliver another dose of the composition.As an example, the capsule can be configured to deliver seven doses of a composition corresponding to one week of treatment.

[0050] An unshown control system allows for the control of LED illumination, piston actuation, and the delivery of the composition to the skin. Preferably, the illumination and composition delivery are controlled simultaneously.

[0051] A person skilled in the art will be able to adapt the device of the invention according to the process of the invention applied. For example, for a composition containing an extract of... Epilobium fleischeri and illumination, particularly at 520nm, the LEDs 29 or part of the LEDs 29 are configured to emit at 520nm and the composition contained in the reservoir 43 of the capsule 13 includes the extract of Epilobium fleischeri.For a method of the invention in which the illumination is done according to the illumination program 2, at 520 nm, 660 nm and 440 nm, the LEDs 29 or part of the LEDs 29 are configured to emit respectively at 520 nm, 660 nm and 440 nm.

[0052] For example, the figure 14This illustrates an embodiment of the electroluminescent device of the invention 32, and more particularly of the assembly of LEDs 29a, 29b, and 29c on the electronic board 34. In this example, there are nine LEDs, distributed circumferentially around the electronic board 34 by the piston 46 that passes through the board. Reference numbers 29a correspond to the LEDs emitting at 660 nm, 29b to the LEDs emitting at 440 nm, and 29c to the LEDs emitting at 520 nm. The control system (not shown) can activate all or part of the LEDs, thus implementing either a method according to the invention involving illumination at 520 nm only, or a method according to the invention involving illumination according to the illumination program 2.

Claims

1. Non-therapeutic cosmetic treatment method comprising at least the steps of: - applying to the skin of a subject an active composition comprising at least one extract of Epilobium fleischeri, and - illuminating the skin with at least one light source emitting at a wavelength between 490 and 550 nanometres, preferably 520 nanometres, the illumination being carried out before, simultaneously with or after the application of the composition.

2. Method according to the preceding claim, wherein the active composition further comprises salicylic acid.

3. Method according to any one of the preceding claims, wherein the active composition further comprises artichoke extract.

4. Method according to any one of the preceding claims, wherein the active composition further comprises niacinamide, and in that the illumination of the skin is further carried out by a light source emitting at a wavelength between 620 and 690 nanometres, preferably 660 nanometres.

5. Method according to any one of the preceding claims, wherein the illumination of the skin is further carried out by a light source emitting at a wavelength between 410 and 470 nanometres, preferably between 440 and 450 nanometres.

6. Process according to any one of the preceding claims, wherein the mass percentage of Epilobium extract in the composition is between 0.1 and 10%.

7. Non-therapeutic cosmetic treatment device comprising at least means for applying to the skin of a subject an active composition comprising at least one extract of Epilobium fleischeri, which active composition is contained in the application means, and means for illuminating the skin with at least one light source emitting at a wavelength between 490 and 550 nanometres, preferably 520 nanometres, the means for illuminating and applying the active composition being configured so that illumination can be carried out before, simultaneously with or after application of the composition.

8. Device according to the preceding claim, wherein the active composition further comprises niacinamide, and in that the means for illuminating the skin further comprise a light source emitting at a wavelength between 620 and 690 nanometres, preferably 660 nanometres.

9. Device according to the preceding claim, wherein the active composition further comprises salicylic acid and artichoke extract, and in that the skin illumination means further comprise a light source emitting at a wavelength between 410 and 470 nanometres, preferably between 440 and 450 nanometres.